Trial record 1 of 1 for:    gog-0277
Previous Study | Return to List | Next Study

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Gynecologic Oncology Group
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Gynecologic Oncology Group
ClinicalTrials.gov Identifier:
NCT01533207
First received: February 11, 2012
Last updated: March 25, 2014
Last verified: March 2014
  Purpose

This randomized phase III trial studies how well gemcitabine hydrochloride and docetaxel followed by doxorubicin hydrochloride work compared to observation in treating patients with high-risk uterine leiomyosarcoma previously removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether combination therapy after surgery is an effective treatment for uterine leiomyosarcoma.


Condition Intervention Phase
Stage I Uterine Sarcoma
Uterine Leiomyosarcoma
Drug: doxorubicin hydrochloride
Drug: gemcitabine hydrochloride
Drug: docetaxel
Biological: filgrastim
Biological: pegfilgrastim
Other: clinical observation
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma

Resource links provided by NLM:


Further study details as provided by Gynecologic Oncology Group:

Primary Outcome Measures:
  • Overall survival [ Time Frame: From study entry to time of death or the date of last contact, assessed up to 5 years ] [ Designated as safety issue: No ]
    The logrank test will be used to test the null hypothesis of independence between survival and randomized treatment. Kaplan-Meier estimates will be used to graph survival distribution curves for each treatment arm. The death hazard ratio (experimental to control) will be estimated using a Cox Proportional Hazards model and a 95% Wald confidence interval will be reported.


Secondary Outcome Measures:
  • Recurrence-free survival [ Time Frame: From study entry to time of recurrence or death, whichever occurs first, assessed up to 5 years ] [ Designated as safety issue: No ]
    The recurrence or death hazard ratio (experimental to control) will be estimated using Cox's proportional hazards model and a 95% Wald confidence interval will be reported. The logrank test will be used to test the null hypothesis of independence between recurrence-free survival and randomized treatment.

  • Frequency and severity of adverse events as assessed by NCI Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 216
Study Start Date: June 2012
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (chemotherapy)
Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo CT and/or MRI. Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.
Drug: doxorubicin hydrochloride
Given IV
Other Names:
  • ADM
  • ADR
  • Adria
  • Adriamycin PFS
  • Adriamycin RDF
Drug: gemcitabine hydrochloride
Given IV
Other Names:
  • dFdC
  • difluorodeoxycytidine hydrochloride
  • gemcitabine
  • Gemzar
Drug: docetaxel
Given IV
Other Names:
  • RP 56976
  • Taxotere
  • TXT
Biological: filgrastim
Given subcutaneously (SC)
Other Names:
  • G-CSF
  • Neupogen
Biological: pegfilgrastim
Given SC
Other Names:
  • Filgrastim SD-01
  • GCSF-SD01
  • Neulasta
  • SD-01 sustained duration G-CSF
Arm II (no treatment)
Patients undergo clinical observation.
Other: clinical observation
Patients followed clinically
Other Name: observation

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine whether overall survival of patients with uterus-limited high-grade leiomyosarcoma is superior among patients assigned to treatment with adjuvant gemcitabine hydrochloride plus docetaxel followed by doxorubicin hydrochloride compared to patients assigned to observation.

SECONDARY OBJECTIVES:

I. To determine whether treatment with adjuvant gemcitabine plus docetaxel followed by doxorubicin improves recurrence-free survival of patients with uterus-limited high-grade leiomyosarcoma compared to observation.

II. To explore the impact of potential predictors of recurrence or death such as patient age, institution-reported tumor size, cervix involvement (yes or no), and mitotic rate. (exploratory)

OUTLINE: This is a multicenter study. Patients are stratified according to country of treating site. Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo computed tomography (CT) and/or magnetic resonance imaging (MRI). Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.

Arm II: Patients undergo clinical observation.

Patients may undergo tumor tissue sample collection at baseline for future correlative studies.

After completion of study treatment, patients in both arms are followed up every 4 months for 3 years and then every 6 months for 2 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with high-risk uterine leiomyosarcoma (LMS), International Federation of Gynecology and Obstetrics (FIGO) stage I (confined to corpus +/- cervix); patients with known uterine serosa involvement are not eligible; patients should have had, at least, a complete hysterectomy (including removal of the cervix); bilateral salpingo-oophorectomy (BSO) is not required

    • Institutional pathology review calls the uterine leiomyosarcoma "high grade"
    • Additionally, if the pathology report indicates a mitotic rate, the mitotic rate should be greater than or equal to 5 mitoses/10 high-power field
    • All patients must be no longer than 12 weeks (3 months) from surgical resection of cancer at the time of enrollment on study; if a patient requires a second operation to complete her surgery, i.e., trachelectomy to remove the cervix and/or BSO, the 12 weeks may be counted from the time of the second operation
    • Patients who had a "morcellation" hysterectomy procedure that involved morcellation within the peritoneal cavity are eligible IF a second operation is performed and biopsies from the second procedure show no evidence of leiomyosarcoma
  • All patients must have no evidence of persistent or metastatic disease as documented by a post-resection computed tomography (CT) of the chest/abdomen/pelvis or by CT chest + magnetic resonance imaging (MRI) abdomen/pelvis; the post-resection imaging studies should be performed within 4 weeks of registration on study
  • Absolute neutrophil count (ANC) greater than or equal to 1,500/mcL (ANC >= 1.5 x 10^9/L)
  • Platelets greater than or equal to 100,000/mcL (platelets >= 100 x 10^9/L)
  • Hemoglobin greater than 8.0 g/dL (= 80 g/L or 4.9 mmol/L)
  • Creatinine less than or equal to 1.5 x institutional upper limit of normal (ULN)
  • Bilirubin* within normal range
  • Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST])* and serum glutamic pyruvate transaminase(SGPT) (alanine aminotransferase [ALT])* less than or equal to 2.5 times ULN
  • Alkaline phosphatase* less than or equal to 2.5 x ULN
  • * Patients with a history of Gilbert's syndrome may be eligible provided total bilirubin is less than or equal to 1.5 x ULN and the AST, ALT, and alkaline phosphatase meet the criteria detailed
  • Neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events(CTCAE) grade 1
  • Patients with Gynecologic Oncology Group (GOG) performance status (PS) of 0 or 1 OR Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 OR Karnofsky PS >= 80%
  • Patients must have signed an approved informed consent
  • Patients participating through U.S. sites must sign an approved and authorization permitting release of personal health information
  • Patients should be free of active infection requiring antibiotics (with the exception of an uncomplicated urinary tract infection [UTI])

Exclusion Criteria:

  • Patients who have had prior therapy with docetaxel, gemcitabine hydrochloride, or doxorubicin hydrochloride at any time in their history
  • Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are ineligible if there is any evidence of other malignancy being present within the last five years
  • Patients are ineligible if their previous cancer treatment contraindicates this protocol therapy
  • Patients with a history of severe hypersensitivity reaction to Taxotere (docetaxel) or other drugs formulated with polysorbate 80
  • Patients with GOG performance status of 2, 3 or 4; or ECOG performance status of 2, 3 or 4
  • Patients who are breast-feeding
  • Patients with a known history of congestive heart failure or cardiac ejection fraction < 50% (or less than institutional normal limits); echocardiogram (ECHO) or multigated acquisition scan (MUGA) is not required prior to enrollment; for patients assigned to the chemotherapy arm, an ECHO or MUGA should be done within 6 months of day 1 of gemcitabine-docetaxel treatment

    • Patients who enroll on study and are randomized to Regimen I (chemotherapy ) and then are found on baseline ECHO or MUGA to have cardiac ejection fraction < 50% or below institutional normal will remain ON study; such patients will receive gemcitabine + docetaxel for 4 cycles but will NOT receive any doxorubicin treatment; they will continue treatment follow-up as outlined for all patients assigned to Regimen I
  • Patients with a history of whole pelvic radiation
  • Concurrent treatment with hormone replacement therapy is permitted at the discretion of the treating physician; patients who have been taking hormonal/hormone-blocking agents for breast cancer or breast cancer prevention or other indication are eligible; use of anti-hormonal agents (tamoxifen, medroxyprogesterone, aromatase inhibitors) is permitted at the discretion of the treating physician
  • Patients with recurrent uterine LMS
  • Patients who are known to be human immunodeficiency virus (HIV) positive are not eligible
  • Patients with gross residual or metastatic tumor findings following complete surgical treatment for uterine LMS
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01533207

  Hide Study Locations
Locations
United States, California
Kaiser Permanente-Deer Valley Medical Center Recruiting
Antioch, California, United States, 94531
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Providence Saint Joseph Medical Center/Disney Family Cancer Center Recruiting
Burbank, California, United States, 91505
Contact: Richard L. Friedman    818-847-3220      
Principal Investigator: Richard L. Friedman         
Kaiser Permanente, Fremont Recruiting
Fremont, California, United States, 94538
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente Recruiting
Fresno, California, United States, 93720
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente, Hayward Recruiting
Hayward, California, United States, 94545
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
UC San Diego Moores Cancer Center Recruiting
LA Jolla, California, United States, 92093
Contact: Michael T. McHale    858-822-5354    cancercto@ucsd.edu   
Principal Investigator: Michael T. McHale         
Kaiser Permanente-Modesto Recruiting
Modesto, California, United States, 95356
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Palo Alto Medical Foundation-Gynecologic Oncology Recruiting
Mountain View, California, United States, 94040
Contact: Albert L. Pisani    650-934-7000      
Principal Investigator: Albert L. Pisani         
Kaiser Permanente-Oakland Recruiting
Oakland, California, United States, 94611
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-Redwood City Recruiting
Redwood City, California, United States, 94063
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-Richmond Recruiting
Richmond, California, United States, 94801
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-Roseville Recruiting
Roseville, California, United States, 95661
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-South Sacramento Recruiting
Sacramento, California, United States, 95823
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente - Sacramento Recruiting
Sacramento, California, United States, 95825
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-San Francisco Recruiting
San Francisco, California, United States, 94115
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-Santa Teresa-San Jose Recruiting
San Jose, California, United States, 95119
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-San Rafael Recruiting
San Rafael, California, United States, 94903
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente Medical Center - Santa Clara Recruiting
Santa Clara, California, United States, 95051
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-Santa Rosa Recruiting
Santa Rosa, California, United States, 95403
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-South San Francisco Recruiting
South San Francisco, California, United States, 94080
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-Stockton Recruiting
Stockton, California, United States, 95210
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente Medical Center-Vacaville Recruiting
Vacaville, California, United States, 95688
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-Vallejo Recruiting
Vallejo, California, United States, 94589
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Kaiser Permanente-Walnut Creek Recruiting
Walnut Creek, California, United States, 94596
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
United States, Connecticut
Hartford Hospital Recruiting
Hartford, Connecticut, United States, 06102
Contact: James S. Hoffman    860-224-5660      
Principal Investigator: James S. Hoffman         
The Hospital of Central Connecticut Recruiting
New Britain, Connecticut, United States, 06050
Contact: James S. Hoffman    860-224-5660      
Principal Investigator: James S. Hoffman         
United States, Delaware
Beebe Medical Center Active, not recruiting
Lewes, Delaware, United States, 19958
Christiana Care Health System-Christiana Hospital Active, not recruiting
Newark, Delaware, United States, 19718
United States, District of Columbia
Sibley Memorial Hospital Recruiting
Washington, District of Columbia, United States, 20016
Contact: Mildred R. Chernofsky    202-243-2373      
Principal Investigator: Mildred R. Chernofsky         
United States, Florida
Florida Hospital Recruiting
Orlando, Florida, United States, 32803
Contact: James E. Kendrick    407-303-5623      
Principal Investigator: James E. Kendrick         
United States, Georgia
Piedmont Hospital Recruiting
Atlanta, Georgia, United States, 30309
Contact: John W. McBroom    404-303-3355    clinicaltrials@northside.com   
Principal Investigator: John W. McBroom         
Dekalb Medical Center Recruiting
Decatur, Georgia, United States, 30033
Contact: Jayanthi Srinivasiah    404-501-3279      
Principal Investigator: Jayanthi Srinivasiah         
Northeast Georgia Medical Center Recruiting
Gainesville, Georgia, United States, 30501
Contact: Andrew E. Green    770-219-8800    cancerpatient.navigator@nghs.com   
Principal Investigator: Andrew E. Green         
United States, Hawaii
Kapiolani Medical Center for Women and Children Recruiting
Honolulu, Hawaii, United States, 96826
Contact: Michael E. Carney    808-983-6090      
Principal Investigator: Michael E. Carney         
Hawaii Minority Based CCOP Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Michael E. Carney    808-983-6090      
Principal Investigator: Michael E. Carney         
Kaiser Permanente Moanalua Medical Center Recruiting
Honolulu, Hawaii, United States, 96819
Contact: Louis Fehrenbacher    626-564-3455      
Principal Investigator: Louis Fehrenbacher         
Queen's Medical Center Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Michael E. Carney    808-983-6090      
Principal Investigator: Michael E. Carney         
Tripler Army Medical Center Recruiting
Honolulu, Hawaii, United States, 96859
Contact: Charles S. Dietrich    808-433-6336      
Principal Investigator: Charles S. Dietrich         
University of Hawaii Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Michael E. Carney    808-983-6090      
Principal Investigator: Michael E. Carney         
United States, Illinois
Rush - Copley Medical Center Recruiting
Aurora, Illinois, United States, 60504
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Seiko D. Yamada    773-834-7424      
Principal Investigator: Seiko D. Yamada         
Mount Sinai Hospital Medical Center Recruiting
Chicago, Illinois, United States, 60608
Contact: Pam G. Khosla    773-257-5960    suhi@sinai.org   
Principal Investigator: Pam G. Khosla         
Northwestern University Active, not recruiting
Chicago, Illinois, United States, 60611
NorthShore University HealthSystem-Evanston Hospital Recruiting
Evanston, Illinois, United States, 60201
Contact: Jean A. Hurteau    847-570-2109      
Principal Investigator: Jean A. Hurteau         
Sudarshan K Sharma MD Limted-Gynecologic Oncology Recruiting
Hinsdale, Illinois, United States, 60521
Contact: Sudarshan K. Sharma    630-856-6757      
Principal Investigator: Sudarshan K. Sharma         
Good Samaritan Regional Health Center Active, not recruiting
Mount Vernon, Illinois, United States, 62864
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
United States, Indiana
Saint Vincent Oncology Center Recruiting
Indianapolis, Indiana, United States, 46260
Contact: Gregory P. Sutton    317-338-2194      
Principal Investigator: Gregory P. Sutton         
Franciscan Saint Anthony Health-Michigan City Recruiting
Michigan City, Indiana, United States, 46360
Contact: Kendrith M. Rowland    800-446-5532      
Principal Investigator: Kendrith M. Rowland         
United States, Iowa
McFarland Clinic PC-William R Bliss Cancer Center Recruiting
Ames, Iowa, United States, 50010
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
Mercy Cancer Center-West Lakes Recruiting
Clive, Iowa, United States, 50325
Contact: Robert J. Behrens    888-244-6061    sherrijr@iora.org   
Principal Investigator: Robert J. Behrens         
Medical Oncology and Hematology Associates-West Des Moines Active, not recruiting
Clive, Iowa, United States, 50325
Iowa Lutheran Hospital Active, not recruiting
Des Moines, Iowa, United States, 50316
Medical Oncology and Hematology Associates-Des Moines Active, not recruiting
Des Moines, Iowa, United States, 50309
Iowa Oncology Research Association CCOP Active, not recruiting
Des Moines, Iowa, United States, 50309
Iowa Methodist Medical Center Active, not recruiting
Des Moines, Iowa, United States, 50309
Medical Oncology and Hematology Associates-Laurel Active, not recruiting
Des Moines, Iowa, United States, 50314
Mercy Medical Center - Des Moines Recruiting
Des Moines, Iowa, United States, 50314
Contact: Robert J. Behrens    888-244-6061    sherrijr@iora.org   
Principal Investigator: Robert J. Behrens         
Mercy Medical Center-Sioux City Recruiting
Sioux City, Iowa, United States, 51104
Contact: Donald B. Wender    712-252-0088      
Principal Investigator: Donald B. Wender         
Saint Luke's Regional Medical Center Recruiting
Sioux City, Iowa, United States, 51104
Contact: Donald B. Wender    712-252-0088      
Principal Investigator: Donald B. Wender         
Siouxland Hematology Oncology Associates Recruiting
Sioux City, Iowa, United States, 51101
Contact: Donald B. Wender    712-252-0088      
Principal Investigator: Donald B. Wender         
Methodist West Hospital Active, not recruiting
West Des Moines, Iowa, United States, 50266-7700
Mercy Medical Center-West Lakes Recruiting
West Des Moines, Iowa, United States, 50266
Contact: Robert J. Behrens    888-244-6061    sherrijr@iora.org   
Principal Investigator: Robert J. Behrens         
United States, Kansas
Cancer Center of Kansas - Chanute Recruiting
Chanute, Kansas, United States, 66720
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Dodge City Recruiting
Dodge City, Kansas, United States, 67801
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - El Dorado Recruiting
El Dorado, Kansas, United States, 67042
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Fort Scott Recruiting
Fort Scott, Kansas, United States, 66701
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Independence Recruiting
Independence, Kansas, United States, 67301
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Kingman Recruiting
Kingman, Kansas, United States, 67068
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Lawrence Memorial Hospital Recruiting
Lawrence, Kansas, United States, 66044
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Liberal Recruiting
Liberal, Kansas, United States, 67901
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Manhattan Recruiting
Manhattan, Kansas, United States, 66502
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - McPherson Recruiting
McPherson, Kansas, United States, 67460
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Newton Recruiting
Newton, Kansas, United States, 67114
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Parsons Recruiting
Parsons, Kansas, United States, 67357
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Pratt Recruiting
Pratt, Kansas, United States, 67124
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Salina Recruiting
Salina, Kansas, United States, 67401
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Wellington Recruiting
Wellington, Kansas, United States, 67152
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Wichita CCOP Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Associates In Womens Health Recruiting
Wichita, Kansas, United States, 67208
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Wichita Medical Arts Tower Recruiting
Wichita, Kansas, United States, 67208
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Wesley Medical Center Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Via Christi Regional Medical Center Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Main Office Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Winfield Recruiting
Winfield, Kansas, United States, 67156
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
United States, Maryland
Johns Hopkins University-Sidney Kimmel Cancer Center Recruiting
Baltimore, Maryland, United States, 21287
Contact: Deborah K. Armstrong    410-955-8804    jhcccro@jhmi.edu   
Principal Investigator: Deborah K. Armstrong         
University of Maryland Greenebaum Cancer Center Recruiting
Baltimore, Maryland, United States, 21201-1595
Contact: Sarah M. Temkin    800-888-8823      
Principal Investigator: Sarah M. Temkin         
Union Hospital of Cecil County Terminated
Elkton MD, Maryland, United States, 21921
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Suzanne George    866-790-4500      
Principal Investigator: Suzanne George         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Suzanne George    866-790-4500      
Principal Investigator: Suzanne George         
United States, Michigan
Bixby Medical Center Recruiting
Adrian, Michigan, United States, 49221
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Hickman Cancer Center Recruiting
Adrian, Michigan, United States, 49221
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Wayne State University-Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Robert T. Morris    313-576-9363      
Principal Investigator: Robert T. Morris         
Borgess Medical Center Recruiting
Kalamazoo, Michigan, United States, 49001
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
Bronson Methodist Hospital Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
Community Cancer Center of Monroe Recruiting
Monroe, Michigan, United States, 48162
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Mercy Memorial Hospital Recruiting
Monroe, Michigan, United States, 48162
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39216
Contact: James T. Thigpen    601-815-6700      
Principal Investigator: James T. Thigpen         
United States, Missouri
Central Care Cancer Center-Carrie J Babb Cancer Center Active, not recruiting
Bolivar, Missouri, United States, 65613
CoxHealth Cancer Center Active, not recruiting
Branson, Missouri, United States, 65616
Southeast Cancer Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: Alan P. Lyss    800-392-0936      
Principal Investigator: Alan P. Lyss         
Capital Region Medical Center-Goldschmidt Cancer Center Recruiting
Jefferson City, Missouri, United States, 65109
Contact: Alan P. Lyss    800-392-0936      
Principal Investigator: Alan P. Lyss         
Freeman Health System Active, not recruiting
Joplin, Missouri, United States, 64804
Mercy Hospital-Joplin Active, not recruiting
Joplin, Missouri, United States, 64804
Saint John's Clinic-Rolla-Cancer and Hematology Active, not recruiting
Rolla, Missouri, United States, 65401
Phelps County Regional Medical Center Active, not recruiting
Rolla, Missouri, United States, 65401
Missouri Baptist Medical Center Recruiting
Saint Louis, Missouri, United States, 63131
Contact: Alan P. Lyss    800-392-0936      
Principal Investigator: Alan P. Lyss         
Saint John's Mercy Medical Center Active, not recruiting
Saint Louis, Missouri, United States, 63141
Saint Louis Cancer and Breast Institute-South City Active, not recruiting
Saint Louis, Missouri, United States, 63109
Mercy Hospital Springfield Active, not recruiting
Springfield, Missouri, United States, 65804
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield Recruiting
Springfield, Missouri, United States, 65802
Contact: Jay W. Carlson    888-244-6061    sherrijr@iora.org   
Principal Investigator: Jay W. Carlson         
CoxHealth South Hospital Active, not recruiting
Springfield, Missouri, United States, 65807
United States, Montana
Montana Cancer Consortium CCOP Active, not recruiting
Billings, Montana, United States, 59101
Billings Clinic Active, not recruiting
Billings, Montana, United States, 59107-7000
Saint Vincent Healthcare Active, not recruiting
Billings, Montana, United States, 59101
Hematology-Oncology Centers of the Northern Rockies PC Terminated
Billings, Montana, United States, 59102
Bozeman Deaconess Cancer Center Terminated
Bozeman, Montana, United States, 59715
Bozeman Deaconess Hospital Active, not recruiting
Bozeman, Montana, United States, 59715
Saint James Community Hospital and Cancer Treatment Center Active, not recruiting
Butte, Montana, United States, 59701
Benefis Healthcare- Sletten Cancer Institute Active, not recruiting
Great Falls, Montana, United States, 59405
Great Falls Clinic Terminated
Great Falls, Montana, United States, 59405
Northern Montana Hospital Terminated
Havre, Montana, United States, 59501
Saint Peter's Community Hospital Active, not recruiting
Helena, Montana, United States, 59601
Kalispell Medical Oncology Terminated
Kalispell, Montana, United States, 59901
Kalispell Regional Medical Center Active, not recruiting
Kalispell, Montana, United States, 59901
Glacier Oncology PLLC Terminated
Kalispell, Montana, United States, 59901
Montana Cancer Specialists Active, not recruiting
Missoula, Montana, United States, 59802
Saint Patrick Hospital - Community Hospital Active, not recruiting
Missoula, Montana, United States, 59802
United States, Nebraska
Nebraska Methodist Hospital Recruiting
Omaha, Nebraska, United States, 68114
Contact: Peter C. Morris    402-354-7939    kathryn.bartz@nmhs.org   
Principal Investigator: Peter C. Morris         
United States, Nevada
Women's Cancer Center of Nevada Recruiting
Las Vegas, Nevada, United States, 89169
Contact: Nicola M. Spirtos    702-851-4672      
Principal Investigator: Nicola M. Spirtos         
United States, New Jersey
Cooper Hospital University Medical Center Recruiting
Camden, New Jersey, United States, 08103
Contact: David P. Warshal    856-325-6757      
Principal Investigator: David P. Warshal         
Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County Recruiting
Mount Holly, New Jersey, United States, 08060
Contact: Randolph B. Deger    888-847-8823      
Principal Investigator: Randolph B. Deger         
Virtua West Jersey Hospital Voorhees Recruiting
Voorhees, New Jersey, United States, 08043
Contact: Randolph B. Deger    888-847-8823      
Principal Investigator: Randolph B. Deger         
United States, New Mexico
Southwest Gynecologic Oncology Associates Inc Recruiting
Albuquerque, New Mexico, United States, 87106
Contact: Carolyn Y. Muller    505-272-6972      
Principal Investigator: Carolyn Y. Muller         
University of New Mexico Recruiting
Albuquerque, New Mexico, United States, 87106
Contact: Carolyn Y. Muller    505-272-6972      
Principal Investigator: Carolyn Y. Muller         
United States, New York
Women's Cancer Care Associates LLC Recruiting
Albany, New York, United States, 12208
Contact: Thomas P. Morrissey    518-458-1390      
Principal Investigator: Thomas P. Morrissey         
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Martee L. Hensley    212-639-7202      
Principal Investigator: Martee L. Hensley         
Stony Brook University Medical Center Recruiting
Stony Brook, New York, United States, 11794
Contact: Michael L. Pearl    800-862-2215      
Principal Investigator: Michael L. Pearl         
State University of New York Upstate Medical University Active, not recruiting
Syracuse, New York, United States, 13210
United States, North Carolina
Carolinas Medical Center Recruiting
Charlotte, North Carolina, United States, 28203
Contact: Robert V. Higgins    704-355-2884      
Principal Investigator: Robert V. Higgins         
Carolinas Medical Center - Northeast Recruiting
Concord, North Carolina, United States, 28025
Contact: Brigitte E. Miller    704-403-1520      
Principal Investigator: Brigitte E. Miller         
Duke University Medical Center Active, not recruiting
Durham, North Carolina, United States, 27710
Cone Health Cancer Center Recruiting
Greensboro, North Carolina, United States, 27403
Contact: James M. Granfortuna    336-832-0821      
Principal Investigator: James M. Granfortuna         
Annie Penn Memorial Hospital Recruiting
Reidsville, North Carolina, United States, 27320
Contact: James M. Granfortuna    336-832-0821      
Principal Investigator: James M. Granfortuna         
United States, North Dakota
Bismarck Cancer Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: John T. Reynolds    701-323-5760    tfischer@mohs.org   
Principal Investigator: John T. Reynolds         
Mid Dakota Clinic Terminated
Bismarck, North Dakota, United States, 58501
Saint Alexius Medical Center Terminated
Bismarck, North Dakota, United States, 58501
Sanford Bismarck Medical Center Withdrawn
Bismarck, North Dakota, United States, 58501
United States, Ohio
Summa Akron City Hospital/Cooper Cancer Center Recruiting
Akron, Ohio, United States, 44304
Contact: Vivian E. von Gruenigen    330-375-6101      
Principal Investigator: Vivian E. von Gruenigen         
Strecker Cancer Center-Belpre Recruiting
Belpre, Ohio, United States, 45714
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Toledo Clinic Cancer Centers-Bowling Green Recruiting
Bowling Green, Ohio, United States, 43402
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Aultman Health Foundation Recruiting
Canton, Ohio, United States, 44710
Contact: Michael P. Hopkins    330-363-6891      
Principal Investigator: Michael P. Hopkins         
Adena Regional Medical Center Recruiting
Chillicothe, Ohio, United States, 45601
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Contact: Steven E. Waggoner    800-641-2422      
Principal Investigator: Steven E. Waggoner         
Mount Carmel Health Center West Recruiting
Columbus, Ohio, United States, 43222
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Doctors Hospital Recruiting
Columbus, Ohio, United States, 43228
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Columbus CCOP Recruiting
Columbus, Ohio, United States, 43215
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Columbus Oncology and Hematology Associates Inc Recruiting
Columbus, Ohio, United States, 43214
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: David M. O'Malley    866-627-7616    osu@emergingmed.com   
Principal Investigator: David M. O'Malley         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Grant Medical Center Recruiting
Columbus, Ohio, United States, 43215
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Riverside Methodist Hospital Recruiting
Columbus, Ohio, United States, 43214
Contact: Jeffrey G. Bell    614-566-4475      
Principal Investigator: Jeffrey G. Bell         
Grady Memorial Hospital Recruiting
Delaware, Ohio, United States, 43015
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Delaware Health Center-Grady Cancer Center Recruiting
Delaware, Ohio, United States, 43015
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Fairfield Medical Center Recruiting
Lancaster, Ohio, United States, 43130
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Lima Memorial Hospital Recruiting
Lima, Ohio, United States, 45804
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Marietta Memorial Hospital Recruiting
Marietta, Ohio, United States, 45750
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Toledo Clinic Cancer Centers-Maumee Recruiting
Maumee, Ohio, United States, 43537
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center Recruiting
Maumee, Ohio, United States, 43537
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Lake University Ireland Cancer Center Recruiting
Mentor, Ohio, United States, 44060
Contact: Steven E. Waggoner    800-641-2422      
Principal Investigator: Steven E. Waggoner         
Knox Community Hospital Recruiting
Mount Vernon, Ohio, United States, 43050
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Licking Memorial Hospital Recruiting
Newark, Ohio, United States, 43055
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Toledo Clinic Cancer Centers-Oregon Recruiting
Oregon, Ohio, United States, 43616
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Saint Charles Hospital Recruiting
Oregon, Ohio, United States, 43616
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Southern Ohio Medical Center Recruiting
Portsmouth, Ohio, United States, 45662
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Springfield Regional Medical Center Recruiting
Springfield, Ohio, United States, 45505
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Flower Hospital Recruiting
Sylvania, Ohio, United States, 43560
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Mercy Hospital of Tiffin Recruiting
Tiffin, Ohio, United States, 44883
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Saint Vincent Mercy Medical Center Recruiting
Toledo, Ohio, United States, 43608
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
The Toledo Hospital/Toledo Children's Hospital Terminated
Toledo, Ohio, United States, 43606
Toledo Clinic Cancer Centers-Toledo Recruiting
Toledo, Ohio, United States, 43623
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
University of Toledo Recruiting
Toledo, Ohio, United States, 43614
Contact: Kelly J. Manahan    419-383-6583      
Principal Investigator: Kelly J. Manahan         
Toledo Community Hospital Oncology Program CCOP Recruiting
Toledo, Ohio, United States, 43617
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Mercy Saint Anne Hospital Recruiting
Toledo, Ohio, United States, 43623
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Fulton County Health Center Recruiting
Wauseon, Ohio, United States, 43567
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
Saint Ann's Hospital Recruiting
Westerville, Ohio, United States, 43081
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
Genesis HealthCare System Recruiting
Zanesville, Ohio, United States, 43701
Contact: John P. Kuebler    800-446-5532      
Principal Investigator: John P. Kuebler         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Robert S. Mannel    405-271-4272    julie-traylor@ouhsc.edu   
Principal Investigator: Robert S. Mannel         
Tulsa Cancer Institute Recruiting
Tulsa, Oklahoma, United States, 74146
Contact: Robert S. Mannel    405-271-4272    julie-traylor@ouhsc.edu   
Principal Investigator: Robert S. Mannel         
United States, Pennsylvania
Abington Memorial Hospital Recruiting
Abington, Pennsylvania, United States, 19001
Contact: Parviz Hanjani    215-481-2402      
Principal Investigator: Parviz Hanjani         
Saint Luke's University Hospital-Bethlehem Campus Recruiting
Bethlehem, Pennsylvania, United States, 18015
Contact: Nicholas P. Taylor    610-954-3582    infolink@slhn.org   
Principal Investigator: Nicholas P. Taylor         
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822-2001
Contact: James R. Bosscher    570-271-5251    ehicks@sprg.mercy.net   
Principal Investigator: James R. Bosscher         
Geisinger Medical Center-Cancer Center Hazelton Recruiting
Hazleton, Pennsylvania, United States, 18201
Contact: James R. Bosscher    570-271-5251    ehicks@sprg.mercy.net   
Principal Investigator: James R. Bosscher         
Paoli Memorial Hospital Recruiting
Paoli, Pennsylvania, United States, 19301
Contact: Albert S. DeNittis    866-225-5654      
Principal Investigator: Albert S. DeNittis         
Geisinger Medical Group Recruiting
State College, Pennsylvania, United States, 16801
Contact: James R. Bosscher    570-271-5251    ehicks@sprg.mercy.net   
Principal Investigator: James R. Bosscher         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Bernice L. Robinson-Bennett    610-988-9323      
Principal Investigator: Bernice L. Robinson-Bennett         
Geisinger Wyoming Valley Recruiting
Wilkes-Barre, Pennsylvania, United States, 18711
Contact: James R. Bosscher    570-271-5251    ehicks@sprg.mercy.net   
Principal Investigator: James R. Bosscher         
Lankenau Hospital Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Paul B. Gilman    484-476-2649    wellenbachj@mlhs.org   
Principal Investigator: Paul B. Gilman         
United States, Rhode Island
Women and Infants Hospital Recruiting
Providence, Rhode Island, United States, 02905
Contact: Carolyn K. McCourt    401-274-1122      
Principal Investigator: Carolyn K. McCourt         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Jennifer L. Young Pierce    843-792-9321      
Principal Investigator: Jennifer L. Young Pierce         
United States, Texas
Parkland Memorial Hospital Recruiting
Dallas, Texas, United States, 75235
Contact: David S. Miller    214-648-7097      
Principal Investigator: David S. Miller         
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: David S. Miller    214-648-7097      
Principal Investigator: David S. Miller         
United States, Virginia
Fredericksburg Oncology Inc Recruiting
Fredericksburg, Virginia, United States, 22401
Contact: Rex B. Mowat    517-265-0116      
Principal Investigator: Rex B. Mowat         
United States, Washington
Providence Saint Mary Regional Cancer Center Recruiting
Walla Walla, Washington, United States, 99362
Contact: Robert C. Quackenbush    800-422-6237      
Principal Investigator: Robert C. Quackenbush         
United States, Wisconsin
Aurora Cancer Care-Grafton Recruiting
Grafton, Wisconsin, United States, 53024
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
Aurora BayCare Medical Center Recruiting
Green Bay, Wisconsin, United States, 54311-6519
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
Gundersen Lutheran Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Kurt Oettel    608-775-2385    cancerctr@gundluth.org   
Principal Investigator: Kurt Oettel         
University of Wisconsin Hospital and Clinics Active, not recruiting
Madison, Wisconsin, United States, 53792
Vince Lombardi Cancer Clinic-Marinette Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
Aurora Saint Luke's Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
Froedtert and the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: William H. Bradley    414-805-4380      
Principal Investigator: William H. Bradley         
Aurora Sinai Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53233
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
Vince Lombardi Cancer Clinic - Oshkosh Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
Vince Lombardi Cancer Clinic-Sheboygan Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
Aurora Medical Center in Summit Recruiting
Summit, Wisconsin, United States, 53066
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
Vince Lombardi Cancer Clinic Recruiting
Two Rivers, Wisconsin, United States, 54241
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
Aurora Women's Pavilion of Aurora West Allis Medical Center Recruiting
West Allis, Wisconsin, United States, 53227
Contact: Peter R. Johnson    800-252-2990      
Principal Investigator: Peter R. Johnson         
United States, Wyoming
Rocky Mountain Oncology Active, not recruiting
Casper, Wyoming, United States, 82609
Welch Cancer Center Active, not recruiting
Sheridan, Wyoming, United States, 82801
Sponsors and Collaborators
Gynecologic Oncology Group
Investigators
Principal Investigator: Martee Hensley Gynecologic Oncology Group
  More Information

No publications provided

Responsible Party: Gynecologic Oncology Group
ClinicalTrials.gov Identifier: NCT01533207     History of Changes
Other Study ID Numbers: GOG-0277, NCI-2012-00249, CDR0000724874, IRCI 001, GOG-0277, GOG-0277, U10CA027469
Study First Received: February 11, 2012
Last Updated: March 25, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Leiomyosarcoma
Sarcoma
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Doxorubicin
Gemcitabine
Docetaxel
Lenograstim
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Adjuvants, Immunologic

ClinicalTrials.gov processed this record on July 22, 2014